Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Balovaptan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

NCT05401565
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Balovaptan, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Bellflower, California • Panorama City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 9, 2026, 1:56 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

NCT04049578
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 4 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Staten Island, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 9, 2026, 1:56 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

NCT05399550
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Balovaptan, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 9, 2026, 1:56 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

NCT03504917
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Dothan, Alabama • Phoenix, Arizona • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

NCT02901431
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RO5285119
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
45
States / cities
Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 9, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

NCT04156646
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Balovaptan, Esomeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 9, 2026, 1:56 AM EDT